Pacira BioSciences, Inc.: directors' dealings · United States · SEC (Form 4)

About Pacira BioSciences, Inc.

Pacira BioSciences, Inc. is a U.S.-based biopharmaceutical company listed on the NASDAQ (United States) and focused on non-opioid pain management. The company’s commercial platform is built around injectable therapies and cryoneurolysis solutions used mainly in hospital and outpatient settings. Pacira’s core franchise is EXPAREL, its liposomal bupivacaine product, which has long served as the company’s primary revenue driver. The portfolio was broadened through the acquisition of iovera° in 2019 and ZILRETTA, an extended-release triamcinolone injectable suspension. Strategically, Pacira positions itself as a leader in reducing opioid reliance in perioperative care and selected orthopedic pain indications. ([investor.pacira.com](https://investor.pacira.com/news-releases/news-release-details/pacira-completes-acquisition-myoscience-advancing-leadership-non)) The company is headquartered in Brisbane, California, placing it in a major U.S. life sciences hub. Its business model combines direct commercialization, product revenue generation, and an expanding set of licensing and partnership agreements. In 2024, Pacira reported $697.2 million of net product sales, led by EXPAREL, followed by ZILRETTA and iovera°. That mix highlights a concentrated but meaningful specialty-pharma revenue base, with a small number of branded assets carrying most of the financial performance. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1396814/000110465925041234/tm254483d2_ars.pdf)) From a competitive standpoint, Pacira is differentiated by its non-opioid positioning in a market where demand for opioid-sparing pain solutions remains structurally important in the United States. EXPAREL is supported by proprietary DepoFoam delivery technology, while iovera° offers targeted cryoneurolysis to temporarily interrupt pain signaling. ZILRETTA adds an orthopedics-oriented asset with relevance in osteoarthritis and related pain management. Together, these products give Pacira a niche leadership position in a specialized therapeutic area where clinical adoption, reimbursement, and differentiated product performance matter more than broad primary-care scale. ([investor.pacira.com](https://investor.pacira.com/news-releases/news-release-details/pacira-completes-acquisition-myoscience-advancing-leadership-non)) Recent developments suggest improving commercial momentum. In the fourth quarter of 2025, Pacira reported revenue of $196.9 million and record-high EXPAREL sales, while iovera° also grew year over year. In November 2025, the company announced an exclusive worldwide license agreement with AmacaThera for AMT-143, a long-acting ropivacaine formulation for postsurgical pain, indicating continued pipeline and business-development activity. The company also continued share repurchases, reinforcing a capital-allocation focus alongside operating execution. For investors, Pacira represents a NASDAQ-listed U.S. healthcare name with exposure to the growing non-opioid pain market, balanced by concentration risk across a limited number of flagship products. ([investor.pacira.com](https://investor.pacira.com/news-releases/news-release-details/pacira-biosciences-reports-fourth-quarter-and-full-year-2025?utm_source=openai))